Kommentar

• Literatur

• 1 Davies MJ, DʼAlessio DA, Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461-2498 . doi:10.1007/s00125-018-4729-5
• 2 Avgerinos I, Michailidis T, Liakos A. et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2019;
• 3 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844 . doi:10.1056/NEJMoa1607141
• 4 Kristensen SL, Rorth R, Jhund PS. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7: 776-785 . doi:10.1016/S2213-8587(19)30249-9